Home » Stage III lung cancer, a new therapy improves survival – Focus Tumor news

Stage III lung cancer, a new therapy improves survival – Focus Tumor news

by admin
Stage III lung cancer, a new therapy improves survival – Focus Tumor news

For patients with unresectable stage III non-small cell lung cancer (NSCLC) and with a mutation of the Egfr gene, a new therapeutic opportunity arrives: the osimertinib molecule has in fact demonstrated a notable benefit for these patients in terms of disease-free survival. progression of the disease. The molecule is the first Egfr inhibitor and the first target therapy to demonstrate a benefit for this group of patients, as highlighted by the Phase III LAURA study.

Each year, an estimated 2.4 million people globally are diagnosed with lung cancer, of which 80-85% are non-small cell, the most common form of lung cancer. Approximately 10-15% of NSCLC patients in the United States and Europe, and 30-40% in Asia, have the Egfr mutation. More than one in six patients with NSCLC are diagnosed with unresectable stage III disease (15%).

“The positive results of the LAURA study represent important news and could represent a further step forward for these patients, for whom there is still a great clinical need and to date no targeted therapy is available”, says Filippo de Marinis, director of the Division of Thoracic Oncology of the European Institute of Oncology (Ieo) in Milan and president of Aiot (Italian Association of Thoracic Oncology).

The efficacy of osimertinb was also confirmed in the first-line treatment of a different patient population. “In the FLAURA2 study – underlines de Marinis – conducted in patients with metastatic non-small cell lung cancer and with Egfr mutation, osimertinib in combination with chemotherapy showed an advantage of approximately 9 months more in terms of progression-free survival of disease compared to osimertinib alone, which is the global standard of care in the first line. The combination reduced the risk of disease progression or death by 38% and, at two years, 57% of patients had no disease progression compared to 41% with osimertinib alone”.

These data, concludes de Marinis, “constitute a further step forward in the first line of treatment of metastatic disease with Egfr mutations and the approval by the FDA confirms osimertinib as a fundamental therapy for lung cancer with Egfr mutation both in monotherapy and in combination with chemotherapy and we hope that it can be approved soon in Europe too.”

See also  Yangming Jiaotong University made a major breakthrough in research and development of biotechnology! DNA nanomedicine capsules are expected to detect cancer | TechNews Technology News

breaking latest news © Copyright ANSA

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy